Zoetis announces Apoquel now in full supply

June 8, 2016

The manufacturer says there are no more order limits for this in-demand canine atopic dermatitis treatment.

Been itching to prescribe oclacitinib (Apoquel) to your canine patients with atopic dermatitis? The manufacturer, Zoetis, has announced that is now available to all U.S. veterinarians without order limits.

Introduced more than two years ago, this new formulation of allergic dermatitis treatment in dogs drew much excitement, which turned to frustration when issues with manufacturing meant Zoetis had to halt new prescriptions, leaving the remaining supply only available to dogs already receiving the medication.

Oclacitinib is a Janus kinase (JAK) inhibitor that decreases inflammatory mediators and cytokines that cause pruritus. Initial studies have shown that it is well-tolerated, results in a rapid reduction in pruritus and alleviates lesions in dogs with atopic dermatitis. For more information on Apoquel, go to zoetisus.com.